Navigation Links
Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology
Date:1/27/2009

Scale-up of Zymes' PTS by Albemarle responds to the demand in food, beverage and nutritional markets

BATON ROUGE, La., Jan. 27 /PRNewswire-FirstCall/ -- Leading specialty chemical company, Albemarle Corporation, (NYSE: ALB) and innovative bioscience company, Zymes LLC, have joined forces to scale-up production of Zymes' proprietary "Ubisol-Aqua(TM)" solubilization technology, PTS. The next generation technology promotes the clear dissolution of non-water-soluble vitamins and natural functional ingredients in water, a long sought after capability that allows food, beverage and nutritional supplement manufacturers to effectively add water-insoluble nutrients to liquid products without the typical cloudy effects. This development is expected to significantly increase the commercialization opportunities for these products.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO )

Under the terms of the manufacturing agreement between the two companies, Albemarle manufactures PTS, the lead compound for the Zymes technology. The company leverages its significant GMP manufacturing capabilities to generate PTS in quantities that accelerate its delivery for use in the production of large-scale consumer food and beverage products and nutritional supplements.

Zymes has attained GRAS (Generally Recognized as Safe) status for PTS following submission to the FDA. In addition to expanding opportunities for the aforementioned markets, Zymes' PTS also shows promise as a nanoparticle delivery system for active pharmaceutical ingredients (APIs).

Albemarle is producing Zymes' PTS at the company's South Haven, MI, multi-purpose GMP manufacturing facility, where Albemarle produces more than 20 active p
'/>"/>

SOURCE Albemarle Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Albemarle Enters Ibuprofen Agreement with Dr. Reddys
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. Genencor Appoints New Executive Vice President - Technical Enzymes
4. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
5. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
6. Novozymes Reports Strong 2008 Results
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. CrossFire Beilstein Database Exceeds Ten Million Compounds
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a ... medicine, today announced that it will release fourth quarter ... Tuesday, March 10, 2015 after the close of the ... call and webcast on Tuesday, March 10, 2015 at ... the results and recent corporate developments. For ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 Market ... agreement for quality market research promotion on Internet. ... research reports worked out by DataGroup Booksellers. , ... Market Publishers Ltd, commented on the recent partnership ... DataGroup Booksellers in our team of publishers. Since ...
(Date:2/27/2015)... A paper published today, " Financing ... in Science Translational Medicine, demonstrates the ... the risk associated with investing in the treatment ... of funding for developing so-called "orphan" drugs. ... between scientists at the National Center for Advancing ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... June 16 Wyeth (NYSE: WYE ) (the ... Senior Debentures due 2024 (the "Convertible Debentures") have the right ... to their terms effective on the July 15, 2009 purchase ... in aggregate principal amount of Convertible Debentures outstanding. , ...
... SANTA CRUZ, Calif., June 16 Six prestigious members ... Career Center ( www.BioCareerCenter.com ), the nation,s ... science professionals. , , The NIH has the ... in the country. The six NIH organizations that have ...
... Pharmaceuticals, the proprietary products division of a wholly owned ... PRX ), today announced that its development partner, BioAlliance ... the Food and Drug Administration (FDA) for Loramyc (R) ... If approved, Strativa could launch Loramyc in the ...
Cached Biology Technology:Wyeth Announces Holder Right to Surrender Convertible Debentures 2Wyeth Announces Holder Right to Surrender Convertible Debentures 3Wyeth Announces Holder Right to Surrender Convertible Debentures 4National Institutes of Health Join Nation's Leading Postgrad Bio Jobs Board 2National Institutes of Health Join Nation's Leading Postgrad Bio Jobs Board 3Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA 2
(Date:2/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... groundbreaking payment method. Payment accounts may be selected via ... accessed if both the speech (the word associated with ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... lion (Thylacoleo carnifex) would have made mince meat of ... hyper-carnivores ever squared off in a fight to the ... published in the Journal of Zoology suggests that Thylacoleo ... scissor through hide and flesh to produce major trauma ...
... gigantic palm that flowers itself to death and exists as part ... name will be published in the Botanical Journal of the Linnean ... trunk which towers over 18m high and fan leaves which are ... is the most massive palm ever to be found in Madagascar. ...
... (January 16, 2008) The latest medications can delay the ... its devastating effects. This limitation often makes early detection the ... for as long as possible. Now, a new ... University may allow patients to take a brief, inexpensive test ...
Cached Biology News:Marsupial lion tops African lion in fight to death 2New genus of self-destructive palm found in Madagascar 2New genus of self-destructive palm found in Madagascar 3Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3
...
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Biology Products: